174 related articles for article (PubMed ID: 22284353)
1. Structural biology and drug discovery of difficult targets: the limits of ligandability.
Surade S; Blundell TL
Chem Biol; 2012 Jan; 19(1):42-50. PubMed ID: 22284353
[TBL] [Abstract][Full Text] [Related]
2. Structural biology and drug discovery for protein-protein interactions.
Jubb H; Higueruelo AP; Winter A; Blundell TL
Trends Pharmacol Sci; 2012 May; 33(5):241-8. PubMed ID: 22503442
[TBL] [Abstract][Full Text] [Related]
3. Making drugs on proteins: site-directed ligand discovery for fragment-based lead assembly.
Erlanson DA; Hansen SK
Curr Opin Chem Biol; 2004 Aug; 8(4):399-406. PubMed ID: 15288250
[TBL] [Abstract][Full Text] [Related]
4. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
[TBL] [Abstract][Full Text] [Related]
5. Domain-based small molecule binding site annotation.
Snyder KA; Feldman HJ; Dumontier M; Salama JJ; Hogue CW
BMC Bioinformatics; 2006 Mar; 7():152. PubMed ID: 16545112
[TBL] [Abstract][Full Text] [Related]
6. Interaction between Arabidopsis Brca2 and its partners Rad51, Dmc1, and Dss1.
Dray E; Siaud N; Dubois E; Doutriaux MP
Plant Physiol; 2006 Mar; 140(3):1059-69. PubMed ID: 16415210
[TBL] [Abstract][Full Text] [Related]
7. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
[TBL] [Abstract][Full Text] [Related]
8. Key factors for successful generation of protein-fragment structures requirement on protein, crystals, and technology.
Böttcher J; Jestel A; Kiefersauer R; Krapp S; Nagel S; Steinbacher S; Steuber H
Methods Enzymol; 2011; 493():61-89. PubMed ID: 21371587
[TBL] [Abstract][Full Text] [Related]
9. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
10. Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis.
Edink E; Rucktooa P; Retra K; Akdemir A; Nahar T; Zuiderveld O; van Elk R; Janssen E; van Nierop P; van Muijlwijk-Koezen J; Smit AB; Sixma TK; Leurs R; de Esch IJ
J Am Chem Soc; 2011 Apr; 133(14):5363-71. PubMed ID: 21322593
[TBL] [Abstract][Full Text] [Related]
11. Form follows function: shape analysis of protein cavities for receptor-based drug design.
Weisel M; Proschak E; Kriegl JM; Schneider G
Proteomics; 2009 Jan; 9(2):451-9. PubMed ID: 19142949
[TBL] [Abstract][Full Text] [Related]
12. Tethering: fragment-based drug discovery.
Erlanson DA; Wells JA; Braisted AC
Annu Rev Biophys Biomol Struct; 2004; 33():199-223. PubMed ID: 15139811
[TBL] [Abstract][Full Text] [Related]
13. Predicting druggable binding sites at the protein-protein interface.
Fuller JC; Burgoyne NJ; Jackson RM
Drug Discov Today; 2009 Feb; 14(3-4):155-61. PubMed ID: 19041415
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of filament formation of human Rad51 protein by a small peptide derived from the BRC-motif of the BRCA2 protein.
Nomme J; Takizawa Y; Martinez SF; Renodon-Cornière A; Fleury F; Weigel P; Yamamoto K; Kurumizaka H; Takahashi M
Genes Cells; 2008 May; 13(5):471-81. PubMed ID: 18429819
[TBL] [Abstract][Full Text] [Related]
15. Probing the druggability of protein-protein interactions: targeting the Notch1 receptor ankyrin domain using a fragment-based approach.
Abdel-Rahman N; Martinez-Arias A; Blundell TL
Biochem Soc Trans; 2011 Oct; 39(5):1327-33. PubMed ID: 21936810
[TBL] [Abstract][Full Text] [Related]
16. Drug-like density: a method of quantifying the "bindability" of a protein target based on a very large set of pockets and drug-like ligands from the Protein Data Bank.
Sheridan RP; Maiorov VN; Holloway MK; Cornell WD; Gao YD
J Chem Inf Model; 2010 Nov; 50(11):2029-40. PubMed ID: 20977231
[TBL] [Abstract][Full Text] [Related]
17. Structural parameterization of the binding enthalpy of small ligands.
Luque I; Freire E
Proteins; 2002 Nov; 49(2):181-90. PubMed ID: 12210999
[TBL] [Abstract][Full Text] [Related]
18. What is the relationship between the global structures of apo and holo proteins?
Brylinski M; Skolnick J
Proteins; 2008 Feb; 70(2):363-77. PubMed ID: 17680687
[TBL] [Abstract][Full Text] [Related]
19. Roles of the human Rad51 L1 and L2 loops in DNA binding.
Matsuo Y; Sakane I; Takizawa Y; Takahashi M; Kurumizaka H
FEBS J; 2006 Jul; 273(14):3148-59. PubMed ID: 16780572
[TBL] [Abstract][Full Text] [Related]
20. Structural biology contributions to tyrosine kinase drug discovery.
Cowan-Jacob SW; Möbitz H; Fabbro D
Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
